Channel: Clinical Research http://journal23.magtechjournal.com/Jwk3_gjyyws EN-US http://journal23.magtechjournal.com/Jwk3_gjyyws/EN/1007-1245/current.shtml http://journal23.magtechjournal.com/Jwk3_gjyyws 1007-1245 http://journal23.magtechjournal.com/Jwk3_gjyyws/EN/10.3760/cma.j.issn.1007-1245.2021.06.025 http://journal23.magtechjournal.com/Jwk3_gjyyws/EN/10.3760/cma.j.issn.1007-1245.2021.06.026 http://journal23.magtechjournal.com/Jwk3_gjyyws/EN/10.3760/cma.j.issn.1007-1245.2021.06.027 Objective To evaluate the value of periodontal pulp combined with semiconductor laser in the treatment of severe periodontitis. Methods A total of 86 patients with severe periodontitis (86 teeth) from June 2017 to June 2019 were selected by simple random sampling. They were divided into two groups by drawing lots, 43 cases in each group. The control group received periodontal pulp treatment, and the study group received periodontal pulp combined with semiconductor laser therapy. The therapeutic effects of the two groups were compared. Results After treatment, the levels of interleukin-4 (IL-4) and tumor necrosis factor-α (TNF-α) in the study group were (15.82±5.05) ng/L and (0.95±0.12) ng/L, lower than those in the control group [(19.03±5.11) ng/L, (1.06±0.19) ng/L] (both P<0.05); probing depth (PD), loss of attachment (CAL), sulcus bleeding index (SBI) in the study group [(5.18±0.55) mm, (5.46±0.49) mm, (2.62±0.75) mm] were lower than those in the control group [(5.51±0.51) mm, (5.81±0.55) mm, (3.03±0.82) mm] (all P<0.05); the bleeding rate of the study group was 4.65% (2/43), lower than that of the control group [20.93% (9/43)] (P<0.05); the tooth looseness score of the study group [(0.58±0.13)] was lower than that of the control group [(0.72±0.24)] (P<0.05); the total effective rate of the study group was 93.02% (40/43), higher than that of the control group [76.74% (33/43)] (P<0.05). Conclusion In severe periodontitis, the combination of periodontal pulp and semiconductor laser therapy can reduce the inflammatory reaction, improve the periodontal index, and enhance the curative effect.]]> http://journal23.magtechjournal.com/Jwk3_gjyyws/EN/10.3760/cma.j.issn.1007-1245.2021.06.028 Objective To investigate the clinical efficacy of Shakuba Valsartan in the treatment of chronic heart failure. Methods A total of 60 patients who met the inclusion criteria from July 2018 to December 2019 were randomly divided into observation group and control group with 30 patients in each group. The observation group was treated with Shakuba Valsartan on the basis of conventional treatment, and the control group only received conventional treatment for 6 months. After the end of treatment, the differences in cardiac function, brain natriuretic peptide, blood pressure, renal function, efficacy, and other aspects between the two groups were observed. Results After the end of the course of treatment, the clinical efficacy of the patients in the observation group was significantly better than that in the control group [93.33% (28/30) vs. 73.33% (22/30)] (P<0.05), the descend range of NT-proBNP and systolic blood pressure were better than those in the control group (both P<0.05), the protection of renal function was also better than that in the control group (P<0.05). Conclusion Shakuba Valsartan has remarkable treatment effect in patients with chronic heart failure, with more secure treatment process and less adverse reactions, which is an ideal therapeutic schedule for chronic heart failure patients.]]>